UNCY SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate

Sep 29, 2026

8-K

Unicycive Therapeutics Faces Securities Class Action Lawsuit

Sep 28, 2026

8-K

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Business Update

Aug 12, 2026

8-K

Unicycive Therapeutics, Inc. Reports Preliminary Second Quarter 2026 Cash Position

Jul 2, 2026

8-K

Unicycive Therapeutics, Inc. Announces Results of 2025 Annual Meeting of Stockholders

Jun 22, 2026

8-K

Unicycive Therapeutics Increases "At-the-Market" Offering Capacity to $150 Million

Jun 5, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

November 2025 ATM | Amount sold to date: $43,750,000

Nov 14, 2025

424B5

June 2025 ATM | Amount sold to date: $3,977,506

Jun 13, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 50,000,000

Jul 16, 2024

424B4

Jul 14, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-3

[No Baby Shelf]* June 2026 SHELF + ATM

Jun 5, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 5, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Apr 1, 2025

S-3

SHELF | ATM | Offering amount: $100,000,000.00 EFFECTIVE

Nov 13, 2024

POS AM

Form POS AM - Post-Effective amendments for registration statement

Nov 13, 2024

S-3

SHELF EFFECTIVE

Jul 5, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A